Imagion Biosystems has released “Notice Pursuant to Section 708A(5)(e) of the Corporations Act.”
Read the notice.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal